Article ; Online: Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.
2012 Volume 118, Issue 14, Page(s) 3565–3570
Abstract: Background: Although convincing data exist regarding the prognostic utility of positron emission tomographic (PET)-computed tomographic (CT) imaging in Hodgkin lymphoma and diffuse large B-cell lymphoma, its prognostic utility both during treatment and ... ...
| Abstract | Background: Although convincing data exist regarding the prognostic utility of positron emission tomographic (PET)-computed tomographic (CT) imaging in Hodgkin lymphoma and diffuse large B-cell lymphoma, its prognostic utility both during treatment and immediately after treatment have not been systematically evaluated in a large mantle cell lymphoma (MCL) patient cohort to support its use in clinical practice. Methods: The authors conducted a retrospective cohort study to examine the prognostic utility of PET-CT imaging in a uniform MCL patient cohort undergoing dose-intensive chemotherapy (R-HyCVAD) in the frontline setting. The primary study endpoints were progression-free survival (PFS) and overall survival (OS). PET-CT images were centrally reviewed for the purposes of this study using standardized response criteria. Results: Fifty-three patients with advanced stage MCL with PET-CT data were identified. With median follow-up of 32 months, 3-year PFS and OS estimates were 76% (95% confidence interval [CI], 64%-84%) and 84% (95% CI, 72%-90%), respectively. Interim PET-CT status was not associated with PFS (hazard ratio [HR], 0.9; 95% CI, 0.3-2.7; P = .8) or OS (HR, 0.6; 95% CI, 0.1-2.9; P = .5). Post-treatment PET-CT status was statistically significantly associated with PFS (HR, 5.2; 95% CI, 2.0-13.6; P = .001) and trended toward significant for OS (HR, 2.8; 95% CI, 0.8-9.6; P = .07). Conclusions: These data do not support the prognostic utility of PET-CT in pretreatment and interim treatment settings. A positive PET-CT after the completion of therapy identifies a patient subset with an inferior PFS and a trend toward inferior OS. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adult ; Aged ; Antibodies, Monoclonal, Murine-Derived/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclophosphamide/therapeutic use ; Dexamethasone/therapeutic use ; Disease-Free Survival ; Doxorubicin/therapeutic use ; Female ; Humans ; Lymphoma, Mantle-Cell/diagnosis ; Lymphoma, Mantle-Cell/drug therapy ; Lymphoma, Mantle-Cell/mortality ; Male ; Middle Aged ; Multimodal Imaging ; Positron-Emission Tomography ; Rituximab ; Tomography, X-Ray Computed ; Treatment Outcome ; Vincristine/therapeutic use | |||||
| Chemical Substances | Antibodies, Monoclonal, Murine-Derived ; Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Dexamethasone (7S5I7G3JQL) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P) | |||||
| Language | English | |||||
| Publishing date | 2012-07-15 | |||||
| Publishing country | United States | |||||
| Document type | Evaluation Studies ; Journal Article ; Multicenter Study | |||||
| ZDB-ID | 1429-1 | |||||
| ISSN | 1097-0142 ; 0008-543X ; 1934-662X | |||||
| ISSN (online) | 1097-0142 | |||||
| ISSN | 0008-543X ; 1934-662X | |||||
| DOI | 10.1002/cncr.26731 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Uh III Zs.146: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.